Raltegravir
Synonym(e)
MK-0518; RGV
Definition
Antiretroviral wirksamer Wirkstoff zur Behandlung der HIV-Infektion. Hemmer der HIV-Integrase (Strangtransfer-Inhibitor).
Dosierung und Art der Anwendung
2mal/Tag 400 mg p.o. angewendet. Eine Boosterung mit Ritonavir ist nicht erforderlich.
Unerwünschte Wirkungen
Selten Übelkeit, Schwindel, Kopfschmerzen, Diarrhoen und Fieber. Aufgrund der Studienlage sind keine Langzeitdaten verfügbar.
Präparate
Isentress
Literatur
- Jones J et al. (2007) Advances in antiretroviral therapy. Top HIV Med 15: 48-82
- Kassahun K et al. (2007) Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35: 1657-1663
- Lataillade M, Kozal MJ (2006) The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 20: 489-501
- Lataillade M, Chiarella J, Kozal MJ (2007) Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12: 563-570
- Markowitz M et al. (2007) Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46: 125-133
- Petitjean G et al. (2007) Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology 4: 60
- Stellbrink HJ (2007) Antiviral Drugs in the Treatment of AIDS: What is in the Pipeline? Eur J Med Res 12: 483-495